Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
doi: 10.1007/s10072-019-04220-8 109
Higher dose exploration (4.5mg trials) Rationale for testing 4.5mg: Investigate maximum tolerable dose Determine if higher = better weight loss Establish safety ceiling Results at 4.5mg weekly: Weight loss: ~12% (vs 10% at 2.4mg) Incremental benefit: Only 2% additional loss Side effects: Significantly worse nausea/vomiting Dropout rate: Higher than 2.4mg Clinical verdict: 4.5mg not recommended for routine use Risk-benefit ratio unfavorable 2.4mg remains optimal Some individuals may tolerate 3.0mg as compromise CagriSema combination dosing trials REDEFINE-1 protocol: Semaglutide: 2.4mg weekly (standard titration over 16 weeks) Cagrilintide: 2.4mg weekly (12-week titration) Both given as separate injections Started simultaneously from week 1 Semaglutide escalation (standard): Weeks 1-4: 0.25mg Weeks 5-8: 0.5mg Weeks 9-12: 1.0mg Weeks 13-16: 1.7mg Week 17+: 2.4mg Cagrilintide escalation (when combined): Weeks 1-4: 0.6mg Weeks 5-8: 1.2mg Weeks 9-12: 1.8mg Week 13+: 2.4mg Results: 15.6% average weight loss (68 weeks) Superior to either alone Side effects manageable with slow titration Combination well-tolerated See our cagrilintide and semaglutide combination guide and semaglutide dosage calculator
doi:10.1371/journal.pone.0040365 Philippova M, Joshi MB, Pfaff D, Kyriakakis E, Maslova K, Erne P, Resink TJ (2012) T-cadherin attenuates insulin-dependent signalling, eNOS activation, and angiogenesis in vascular endothelial cells
Our goal is to empower you with the cleanest, most effective tools for your wellness journey
Are there any downsides to using copper peptides
PLoS ONE 4 , e7798 (2009)
